Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings

MDGL·Reported May 1, 2025·Before market open

Madrigal Pharmaceuticals, Inc. reported Q1 2025 revenue of $137.3M, missed analyst consensus of $158.9M by $21.7M. Diluted EPS came in at $-3.32 (+55.0% YoY), beat the $-3.62 consensus by $0.30.

Revenue
$137.3Mmissed by $21.7M
Consensus: $158.9M
Diluted EPS
$-3.32beat by $0.30
Consensus: $-3.62
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001628280-25-021356

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Madrigal Pharmaceuticals, Inc.'s Q1 2025 earnings report.

Madrigal Pharmaceuticals, Inc. (MDGL) reported Q1 2025 earnings on May 1, 2025 before market open.

Madrigal Pharmaceuticals, Inc. reported revenue of $137.3M and diluted EPS of $-3.32 for Q1 2025.

Revenue missed the consensus estimate of $158.9M by $21.7M. EPS beat the consensus estimate of $-3.62 by $0.30.

Compared to the same quarter a year prior, diluted EPS grew 55.0% from $-7.38.

You can read the 10-Q periodic report (0001628280-25-021356) directly on SEC EDGAR. The filing index links above go to sec.gov.